Advances in the anti-tumor potential of hederagenin and its analogs

Eur J Pharmacol. 2023 Nov 15:959:176073. doi: 10.1016/j.ejphar.2023.176073. Epub 2023 Sep 22.

Abstract

Hederagenin is a pentacyclic triterpenoid that is widely distributed as the main pharmaceutical ingredient in various medicinal plants. Similarly as other pentacyclic triterpenoids, hederagenin has various pharmacological effects such as anti-tumor, anti-inflammatory, anti-depressant, and anti-viral activities. In particular, the anti-tumor activity of hederagenin indicates its potential for development into highly effective chemotherapeutic agents. Studies revealed that hederagenin effectively suppresses the growth of various tumor cell lines in vitro and interacts with several molecular targets that play essential roles in various cellular signaling pathways. The compound suppresses transformation, inhibits proliferation, and induces apoptosis in tumor cells. In this review, we highlight research progress on the source, pharmacokinetics, pharmacological activity, and mechanism of action of hederagenin and the anti-tumor activity of its analogs by integrating and analyzing relevant domestic and international studies and providing a basis for their further development and application.

Keywords: Anti-tumor; Derivatives; Hederagenin; Natural product; Structure–activity relationship.

Publication types

  • Review

MeSH terms

  • Anti-Inflammatory Agents
  • Cell Line, Tumor
  • Oleanolic Acid* / pharmacology
  • Oleanolic Acid* / therapeutic use
  • Pentacyclic Triterpenes

Substances

  • hederagenin
  • Oleanolic Acid
  • Pentacyclic Triterpenes
  • Anti-Inflammatory Agents